These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32256440)

  • 1. The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.
    Fernández Ó; Costa-Frossard L; Martínez-Ginés M; Montero P; Prieto JM; Ramió L
    Front Neurol; 2020; 11():152. PubMed ID: 32256440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
    Fernandez O; Costa-Frossard L; Martínez-Ginés ML; Montero P; Prieto-González JM; Ramió-Torrentà L
    Front Neurol; 2021; 12():722801. PubMed ID: 34646229
    [No Abstract]   [Full Text] [Related]  

  • 3. Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.
    Goicochea Briceño H; Higueras Y; Ruiz Pérez I; García Domínguez JM; Cuello JP; Meldaña Rivera A; Martínez Ginés ML
    Front Neurol; 2024; 15():1360032. PubMed ID: 38469589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis.
    Bruno A; Dolcetti E; Centonze D
    Front Neurol; 2021; 12():802918. PubMed ID: 35197915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nabiximols oromucosal spray (Sativex
    Garde N; Heibel M
    Drugs Context; 2024; 13():. PubMed ID: 38384931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M; Hatschenberger R; Leutmezer F
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
    Chan A; Silván CV
    Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.
    Haddad F; Dokmak G; Karaman R
    Life (Basel); 2022 May; 12(5):. PubMed ID: 35629350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
    Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.
    Flachenecker P; Saccà F; Vila C
    Case Rep Neurol; 2018; 10(2):169-176. PubMed ID: 30140216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
    Haupts MR; Essner U; Mäurer M
    Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis symptoms and spasticity management: new data.
    Izquierdo G
    Neurodegener Dis Manag; 2017 Nov; 7(6s):7-11. PubMed ID: 29143581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.